D. E. Shaw & Co., Inc. Fulcrum Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 625,176 shares of FULC stock, worth $3.85 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

625,176

Previous 497,679 25.62%

Holding current value

$3.85 Million

Previous $3.36 Million 75.68%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.7 - $12.0 $854,229 - $1.53 Million	127,497 Added 25.62%	625,176 $5.9 Million
Q4 2023 Feb 14, 2024	BUY	$3.18 - $6.86 $878,999 - $1.9 Million	276,415 Added 124.93%	497,679 $3.36 Million
Q3 2023 Nov 14, 2023	BUY	$3.25 - $6.08 $243,886 - $456,255	75,042 Added 51.32%	221,264 $982,000
Q2 2023 Aug 14, 2023	BUY	$2.26 - $3.8 $295,831 - $497,416	130,899 Added 854.26%	146,222 $482,000
Q1 2023 May 15, 2023	SELL	$2.83 - $13.99 $455,129 - $2.25 Million	-160,823 Reduced 91.3%	15,323 $43,000

Q4 2022 Feb 14, 2023	BUY	$5.35 - $7.28 $501,867 - $682,914	93,807 Added 113.93%	176,146 $1.28 Million
Q3 2022 Nov 14, 2022	SELL	$4.92 - $9.1 $281,143 - $520,001	-57,143 Reduced 40.97%	82,339 $666,000
Q2 2022 Aug 15, 2022	SELL	$4.2 - $24.0 $1.71 Million - $9.79 Million	-407,922 Reduced 74.52%	139,482 $683,000
Q1 2022 May 16, 2022	SELL	$9.96 - $23.65 $3.04 Million - $7.21 Million	-304,744 Reduced 35.76%	547,404 $12.9 Million
Q4 2021 Feb 14, 2022	BUY	$14.0 - $28.44 $756,658 - $1.54 Million	54,047 Added 6.77%	852,148 $15.1 Million
Q3 2021 Nov 15, 2021	BUY	$7.28 - $30.97 $5.81 Million - $24.7 Million	798,101 New	798,101 $22.5 Million

Others Institutions Holding FULC

# of Institutions

135

Shares Held

43.7M

Call Options Held

3.12M

Put Options Held

128K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $321M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account